Clinical Approach to Weakness
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of weakness
Weakness is one of the most common and clinically significant complaints encountered in neurology, accounting for approximately 5% of all emergency department visits and representing the chief complaint in up to 13% of primary care consultations. Distinguishing true motor weakness from fatigue, malaise, or generalized debility is the critical first step in evaluation. True neuromuscular weakness affects an estimated 1 in 50 adults over their lifetime, with conditions such as stroke affecting 795,000 Americans annually and peripheral neuropathy affecting up to 8% of adults over age 55.
Definition
True weakness (paresis) is the objective reduction in muscle strength resulting from dysfunction anywhere along the motor pathway — from the cerebral cortex to the muscle fiber itself. This must be distinguished from asthenia (subjective sense of weakness without objective strength loss) and fatigue (weakness that develops or worsens with sustained effort). Complete loss of motor function is termed paralysis or plegia.
Classification by Duration
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Hyperacute | Seconds to minutes | Stroke, transient ischemic attack, seizure with postictal paresis | Neurological emergency; consider thrombolysis window |
| Acute | Hours to days | Guillain-Barré syndrome, acute transverse myelitis, myasthenic crisis | Requires urgent evaluation; may need intensive care monitoring |
| Subacute | Days to weeks | Inflammatory myopathy, chronic inflammatory demyelinating polyneuropathy, spinal cord compression | Allows time for systematic workup; treatment often immunomodulatory |
| Chronic | Months to years | Motor neuron disease, hereditary neuropathies, muscular dystrophies | Often progressive; focus on diagnosis and supportive care |
Classification by Pattern of Distribution
Proximal versus Distal
Proximal weakness (shoulder girdle, hip flexors) suggests myopathy or neuromuscular junction disorders. Patients report difficulty climbing stairs, rising from chairs, or lifting arms overhead.
Distal weakness (hands, feet) suggests peripheral neuropathy or motor neuron disease. Patients report foot drop, difficulty with fine motor tasks, or grip weakness.
Symmetric versus Asymmetric
Symmetric weakness suggests systemic or metabolic causes, myopathies, or length-dependent neuropathies.
Asymmetric weakness suggests focal lesions (stroke, radiculopathy), multifocal processes (vasculitic neuropathy), or motor neuron disease.
Classification by Anatomical Localization
| Level | Pattern | Associated Features | Examples |
|---|---|---|---|
| Upper Motor Neuron | Pyramidal distribution (extensors in upper limb, flexors in lower limb) | Spasticity, hyperreflexia, Babinski sign, no significant atrophy early | Stroke, multiple sclerosis, spinal cord lesion |
| Lower Motor Neuron | Follows nerve root, plexus, or peripheral nerve distribution | Flaccidity, hyporeflexia, atrophy, fasciculations | Radiculopathy, peripheral neuropathy, motor neuron disease |
| Neuromuscular Junction | Fatigable weakness; ocular, bulbar, or proximal limb | Fluctuating symptoms, ptosis, diplopia, no sensory loss | Myasthenia gravis, Lambert-Eaton syndrome |
| Muscle | Proximal > distal; symmetric | No sensory loss, reflexes preserved until late, possible myalgia | Inflammatory myopathy, muscular dystrophy |
Special Patterns and Their Significance
| Pattern | Description | Suggests |
|---|---|---|
| Hemiparesis | Weakness of face, arm, and leg on one side | Contralateral hemispheric lesion (stroke, tumor, demyelination) |
| Paraparesis | Weakness of both lower extremities | Spinal cord lesion, bilateral cerebral lesions (parasagittal), cauda equina syndrome |
| Quadriparesis | Weakness of all four limbs | High cervical cord lesion, brainstem lesion, diffuse peripheral process (Guillain-Barré syndrome) |
| Monoparesis | Weakness confined to one limb | Cortical lesion, plexopathy, mononeuropathy, radiculopathy |
| Bulbar weakness | Weakness of speech, swallowing, facial muscles | Brainstem lesion, motor neuron disease, myasthenia gravis, inflammatory myopathy |
| Fatigable weakness | Strength declines with repetitive use; recovers with rest | Neuromuscular junction disorder (myasthenia gravis) |
The Localization Imperative: The single most important task when evaluating weakness is anatomical localization. Before considering specific diagnoses, determine whether the lesion is in the: (1) Upper motor neuron (brain or spinal cord), (2) Lower motor neuron (anterior horn cell, nerve root, plexus, peripheral nerve), (3) Neuromuscular junction, or (4) Muscle. This localization drives the entire diagnostic workup.
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of weakness
Voluntary movement requires the coordinated function of a complex motor pathway extending from the cerebral cortex to the muscle fiber. Weakness results from disruption at any level of this pathway. Understanding the anatomy and physiology of each component is essential for localizing the lesion and guiding investigation. The motor system can be conceptualized as a two-neuron pathway: the upper motor neuron (from cortex to anterior horn) and the lower motor neuron (from anterior horn to muscle), connected to muscle via the neuromuscular junction.
The Motor Pathway
| Component | Structure | Function |
|---|---|---|
| Primary Motor Cortex | Precentral gyrus (Brodmann area 4) | Initiation of voluntary movement; somatotopic organization (motor homunculus) |
| Corticospinal Tract | Corona radiata → internal capsule → cerebral peduncle → medullary pyramid | Transmission of motor commands; 85% decussate at pyramidal decussation |
| Spinal Cord | Lateral corticospinal tract → anterior horn | Relay of upper motor neuron signals to lower motor neurons |
| Anterior Horn Cell | Gray matter of spinal cord ventral horn | Lower motor neuron cell body; final common pathway integration |
| Peripheral Nerve | Ventral root → plexus → peripheral nerve | Conduction of action potentials to neuromuscular junction |
| Neuromuscular Junction | Presynaptic terminal, synaptic cleft, postsynaptic membrane | Chemical transmission via acetylcholine release and receptor binding |
| Muscle Fiber | Sarcolemma, T-tubules, sarcoplasmic reticulum, myofibrils | Excitation-contraction coupling; force generation via actin-myosin interaction |
Upper Motor Neuron versus Lower Motor Neuron Lesions
Upper Motor Neuron (UMN) Features
Pathophysiology: Loss of descending inhibition leads to release of spinal reflex arcs
Tone: Increased (spasticity) — velocity-dependent resistance
Reflexes: Hyperreflexia with clonus
Babinski sign: Present (upgoing plantar response)
Atrophy: Minimal (disuse only, develops late)
Fasciculations: Absent
Distribution: Pyramidal pattern (flexors weak in arm, extensors weak in leg)
Lower Motor Neuron (LMN) Features
Pathophysiology: Loss of trophic support and denervation of muscle fibers
Tone: Decreased (flaccidity)
Reflexes: Hyporeflexia or areflexia
Babinski sign: Absent (flexor or no response)
Atrophy: Prominent and early
Fasciculations: Present (spontaneous motor unit discharges)
Distribution: Follows myotomal, plexus, or peripheral nerve pattern
Mechanisms of Weakness by Anatomical Level
| Level | Mechanism | Clinical Implication |
|---|---|---|
| Cortex/Subcortical | Ischemia, hemorrhage, demyelination, mass effect disrupting motor cortex or descending fibers | Contralateral weakness; face and arm often more affected than leg in middle cerebral artery stroke |
| Brainstem | Infarction affecting corticospinal tract; often with cranial nerve involvement | Crossed deficits (ipsilateral cranial nerve, contralateral limb weakness) |
| Spinal Cord | Compression, inflammation, ischemia, demyelination affecting corticospinal tracts | Level determines pattern; cervical affects all four limbs, thoracic spares arms |
| Anterior Horn Cell | Degeneration (motor neuron disease), viral infection (polio), autoimmune attack | Mixed UMN and LMN signs in amyotrophic lateral sclerosis; pure LMN in spinal muscular atrophy |
| Nerve Root | Compression (disc herniation), inflammation, infiltration | Dermatomal sensory loss with myotomal weakness; radicular pain common |
| Plexus | Trauma, compression, inflammation (plexitis), infiltration (tumor, radiation) | Multiple nerve root and peripheral nerve distributions affected; complex pattern |
| Peripheral Nerve | Demyelination (conduction block), axonal degeneration (Wallerian), compression | Demyelinating causes conduction slowing; axonal causes denervation changes on electromyography |
| Neuromuscular Junction | Autoantibodies against acetylcholine receptors (myasthenia gravis) or presynaptic calcium channels (Lambert-Eaton) | Fatigable weakness; improves with rest or acetylcholinesterase inhibitors in myasthenia gravis |
| Muscle | Inflammatory destruction, genetic defects in structural proteins, metabolic dysfunction | Proximal weakness predominates; creatine kinase elevation common; no sensory involvement |
Neuromuscular Junction Transmission
Normal Transmission
Step 1: Action potential arrives at presynaptic terminal
Step 2: Calcium influx triggers acetylcholine vesicle release
Step 3: Acetylcholine binds postsynaptic receptors
Step 4: End-plate potential triggers muscle action potential
Myasthenia Gravis
Defect: Autoantibodies against acetylcholine receptors
Result: Reduced receptor density and impaired transmission
Clinical effect: Fatigable weakness worsening with repeated use
Safety factor: Reduced; threshold for failure lowered
Lambert-Eaton Syndrome
Defect: Autoantibodies against presynaptic voltage-gated calcium channels
Result: Reduced acetylcholine release
Clinical effect: Weakness that may improve briefly with exercise (facilitation)
Association: Small cell lung cancer in 50-60% of cases
Muscle Fiber Pathophysiology
| Category | Mechanism | Examples | Key Feature |
|---|---|---|---|
| Inflammatory | Immune-mediated destruction of muscle fibers | Polymyositis, dermatomyositis, inclusion body myositis | Elevated creatine kinase; responds to immunosuppression (except inclusion body myositis) |
| Dystrophic | Genetic defects in structural proteins (dystrophin, sarcoglycans) | Duchenne muscular dystrophy, limb-girdle muscular dystrophy | Progressive; onset often in childhood; characteristic patterns |
| Metabolic | Enzyme deficiencies affecting energy metabolism | McArdle disease (myophosphorylase deficiency), mitochondrial myopathies | Exercise intolerance; may have episodic weakness or rhabdomyolysis |
| Toxic/Drug-induced | Direct myotoxicity or immune-mediated damage | Statin myopathy, alcohol, corticosteroids | Temporal relationship to drug exposure; may resolve with discontinuation |
| Endocrine | Hormonal effects on muscle metabolism and protein synthesis | Hypothyroid myopathy, Cushing syndrome, hyperparathyroidism | Reversible with treatment of underlying endocrine disorder |
Often Overlooked: Motor Neuron Disease Has Mixed Signs
Amyotrophic lateral sclerosis (ALS) uniquely affects both upper and lower motor neurons simultaneously. Finding both upper motor neuron signs (hyperreflexia, spasticity, Babinski) and lower motor neuron signs (atrophy, fasciculations) in the same limb is highly suggestive of motor neuron disease. This combination should not occur in isolated upper or lower motor neuron lesions and should prompt urgent referral.
The Sensory Clue: When Weakness Has Sensory Loss
Key Principle: The presence or absence of sensory involvement helps localize the lesion:
- Weakness WITH sensory loss: Suggests lesion involves sensory pathways — brain, spinal cord, nerve root, plexus, or peripheral nerve
- Weakness WITHOUT sensory loss: Suggests pure motor pathology — motor cortex, anterior horn cell, neuromuscular junction, or muscle
- Exception: Some peripheral neuropathies (pure motor neuropathies like multifocal motor neuropathy) spare sensory fibers
3. History Taking
A comprehensive approach to eliciting the weakness history
Red Flags — Require Urgent Evaluation
- Hyperacute onset (seconds to minutes) — Stroke until proven otherwise
- Rapidly ascending weakness — Guillain-Barré syndrome; monitor respiratory function
- Respiratory muscle involvement — Dyspnea, orthopnea, weak cough; may need ventilatory support
- Bulbar symptoms — Dysarthria, dysphagia, drooling; aspiration risk
- Bladder or bowel dysfunction with weakness — Spinal cord compression; MRI within hours
- Weakness with severe pain at specific spinal level — Epidural abscess, metastatic cord compression
- Bilateral leg weakness with sensory level — Transverse myelitis, cord compression
- Ptosis with diplopia and progressive weakness — Myasthenic crisis; risk of respiratory failure
Systematic History: The “WEAKNESS” Approach
Use the mnemonic “WEAKNESS” to ensure comprehensive history taking:
- W — When and How: Onset (sudden, gradual, stepwise), duration, progression pattern
- E — Extent and Distribution: Which muscles? Proximal or distal? Symmetric or asymmetric? Focal or diffuse?
- A — Associated Symptoms: Sensory changes, pain, fatigue, diplopia, dysphagia, breathing difficulty, bladder/bowel
- K — Key Functional Impact: Climbing stairs, rising from chair, lifting arms, grip strength, walking, falls
- N — Neurological History: Prior episodes, known neurological conditions, family history of neuromuscular disease
- E — Exacerbating and Relieving Factors: Exercise effect (fatigue versus facilitation), rest, heat, cold, time of day
- S — Systemic Features: Fever, weight loss, rash, joint pain, malignancy history, recent infections
- S — Substances and Medications: Statins, steroids, alcohol, drugs of abuse, recent immunizations
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Stroke | Sudden onset, unilateral, vascular risk factors | “Exactly what were you doing when it started? Did it come on all at once or build up?” |
| Guillain-Barré syndrome | Ascending paralysis, preceding infection | “Did you have a cold, flu, or diarrheal illness in the 2-4 weeks before this started?” |
| Myasthenia gravis | Fatigable weakness, ocular and bulbar symptoms | “Is your weakness worse at the end of the day? Do your eyelids droop or do you see double?” |
| Inflammatory myopathy | Proximal weakness, difficulty with overhead activities | “Do you have trouble washing your hair, getting up from a low chair, or climbing stairs?” |
| Motor neuron disease (amyotrophic lateral sclerosis) | Progressive, mixed upper and lower motor neuron signs | “Have you noticed muscle twitching under your skin? Any trouble with speech or swallowing?” |
| Spinal cord compression | Back pain, sensory level, sphincter dysfunction | “Do you have back pain? Any numbness below a certain level? Trouble with bladder or bowels?” |
| Peripheral neuropathy | Distal, symmetric, sensory symptoms common | “Did it start in your feet and work upward? Do you have numbness or tingling?” |
| Radiculopathy | Dermatomal pattern, radiating pain | “Does the weakness follow pain that shoots down your arm or leg?” |
| Lambert-Eaton myasthenic syndrome | Proximal weakness, autonomic symptoms, improves briefly with use | “Does your strength improve after a few seconds of exercise? Do you have dry mouth or constipation?” |
| Periodic paralysis | Episodic weakness, triggered by carbohydrates or rest after exercise | “Do you have episodes of weakness that come and go? Does eating carbs or resting after exercise trigger it?” |
Distinguishing True Weakness from Mimics
| Complaint | True Weakness | Fatigue/Asthenia | Key Differentiating Question |
|---|---|---|---|
| “I feel weak” | Cannot perform specific tasks despite trying | Tired, lacks energy to attempt tasks | “Can you lift your arm, or do you just feel too tired to try?” |
| “My legs give out” | Objective leg weakness on examination | Pain-limited, deconditioning, joint instability | “Do your legs actually buckle, or do you stop because of pain or tiredness?” |
| “I can’t grip” | Reduced grip strength measurably | Pain in hand, arthritis limiting grip | “Is it that you can’t squeeze hard, or that squeezing hurts?” |
Medication and Substance History
Medications That Cause Weakness
- Statins — Myopathy (common), rhabdomyolysis (rare); risk increased with high dose, drug interactions
- Corticosteroids — Steroid myopathy; proximal weakness with prolonged use
- Colchicine — Myopathy and neuropathy, especially with renal impairment
- Antiretrovirals (zidovudine) — Mitochondrial myopathy
- Hydroxychloroquine — Myopathy and cardiomyopathy with prolonged use
- Amiodarone — Peripheral neuropathy (axonal)
- Immune checkpoint inhibitors — Myositis, myasthenia gravis, neuropathy
- Fluoroquinolones — Tendinopathy, may exacerbate myasthenia gravis
Social and Exposure History
- Alcohol: Chronic myopathy, peripheral neuropathy; assess quantity and duration
- Illicit drugs: Cocaine (rhabdomyolysis), heroin (compressive neuropathy)
- Occupation: Lead exposure (motor neuropathy), repetitive strain (entrapment)
- Travel: Poliomyelitis (endemic areas), tick paralysis, tropical infections
- Dietary history: Vitamin B12 deficiency (vegans), thiamine deficiency (alcoholics)
- Recent infections: Guillain-Barré syndrome trigger (Campylobacter, cytomegalovirus, Epstein-Barr virus)
- Immunizations: Rare trigger for Guillain-Barré syndrome
Family History: Key Conditions to Ask About
Hereditary Neuromuscular Diseases
Many causes of weakness are genetic. Ask specifically about:
- Muscular dystrophy — “Did anyone in your family use a wheelchair or have muscle wasting?”
- Charcot-Marie-Tooth disease — “Does anyone have high arches, hammer toes, or weak ankles?”
- Myotonic dystrophy — “Does anyone have difficulty releasing their grip, cataracts at a young age, or heart rhythm problems?”
- Hereditary neuropathies — “Did any relatives have numbness or weakness in their feet requiring braces?”
- Periodic paralysis — “Does anyone have episodes of sudden paralysis?”
4. Physical Examination
A systematic neurological approach for weakness
Systematic Framework: The neurological examination for weakness follows a structured approach: General inspection → Vital signs → Cranial nerves → Motor examination → Sensory examination → Reflexes → Coordination → Gait. The goal is to localize the lesion anatomically before considering specific diagnoses.
General Inspection
- Body habitus: Cushingoid features (steroid myopathy), cachexia (malignancy, motor neuron disease)
- Posture and positioning: Asymmetric posture, dropped head (neck extensor weakness), wrist or foot drop
- Muscle bulk: Atrophy (lower motor neuron lesion, disuse), pseudohypertrophy (muscular dystrophy)
- Fasciculations: Visible muscle twitching at rest (lower motor neuron pathology, especially motor neuron disease)
- Skin: Heliotrope rash, Gottron papules (dermatomyositis), café-au-lait spots (neurofibromatosis)
- Assistive devices: Braces, wheelchair, walking aids indicating chronicity and severity
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Respiratory Rate and Pattern | Tachypnea, use of accessory muscles, paradoxical breathing | Respiratory muscle weakness (diaphragm, intercostals); may need urgent ventilatory support |
| Oxygen Saturation | Hypoxemia, especially when supine | Late sign of respiratory muscle failure; check arterial blood gas if concerned |
| Blood Pressure | Orthostatic hypotension, labile blood pressure | Autonomic dysfunction (Guillain-Barré syndrome, Lambert-Eaton syndrome, diabetic neuropathy) |
| Heart Rate | Bradycardia or tachycardia, arrhythmia | Autonomic involvement; cardiac monitoring needed in Guillain-Barré syndrome |
| Temperature | Fever | Infection (abscess, meningitis), inflammatory process; heat worsens myasthenia gravis |
Critical: Bedside Respiratory Assessment
In neuromuscular weakness, respiratory failure can occur rapidly. Assess:
- Single breath count: Ask patient to take a deep breath and count as high as possible — less than 20 suggests reduced vital capacity
- Neck flexion strength: Correlates with diaphragm strength; if weak, respiratory compromise likely
- Forced vital capacity (FVC): Measure serially; FVC less than 20 mL/kg or falling more than 30% indicates impending failure
- Negative inspiratory force (NIF): Weaker than -30 cmH2O suggests need for ventilatory support
Cranial Nerve Examination
| Cranial Nerve | Test | Abnormality and Significance |
|---|---|---|
| II (Optic) | Visual acuity, visual fields, fundoscopy | Papilledema (raised intracranial pressure), optic atrophy (multiple sclerosis) |
| III, IV, VI (Oculomotor, Trochlear, Abducens) | Eye movements, pupil responses | Diplopia, ptosis (myasthenia gravis, third nerve palsy); fatigable ptosis pathognomonic for myasthenia |
| V (Trigeminal) | Facial sensation, jaw strength, jaw jerk | Brisk jaw jerk (upper motor neuron lesion above pons) |
| VII (Facial) | Facial symmetry, eye closure, smile | Upper motor neuron pattern spares forehead; lower motor neuron affects entire hemiface |
| IX, X (Glossopharyngeal, Vagus) | Palate elevation, gag reflex, voice quality | Bulbar weakness (dysarthria, dysphagia, nasal voice); motor neuron disease, myasthenia gravis |
| XI (Accessory) | Shoulder shrug, head turning | Trapezius and sternocleidomastoid weakness |
| XII (Hypoglossal) | Tongue protrusion, bulk, fasciculations | Tongue atrophy and fasciculations highly suggestive of motor neuron disease |
Motor Examination
Muscle Tone
Increased Tone
Spasticity: Velocity-dependent; “clasp-knife” quality; upper motor neuron lesion
Rigidity: Velocity-independent; “lead-pipe” or “cogwheel”; extrapyramidal (not true weakness)
Decreased Tone
Flaccidity: Reduced resistance to passive movement; lower motor neuron lesion, acute upper motor neuron lesion (spinal shock), cerebellar lesion
Muscle Strength Testing: Medical Research Council (MRC) Scale
| Grade | Description | Clinical Interpretation |
|---|---|---|
| 5 | Normal power against full resistance | No weakness |
| 4 | Movement against resistance but reduced | Mild weakness (4+, 4, 4- may be used for gradation) |
| 3 | Movement against gravity but not resistance | Moderate weakness |
| 2 | Movement with gravity eliminated | Severe weakness |
| 1 | Flicker of contraction visible or palpable | Trace movement only |
| 0 | No contraction | Complete paralysis |
Key Muscle Groups to Test
Upper Limb
- Shoulder abduction (C5): Deltoid
- Elbow flexion (C5-C6): Biceps
- Elbow extension (C7): Triceps
- Wrist extension (C6-C7): Wrist extensors
- Finger extension (C7): Finger extensors
- Finger abduction (T1): First dorsal interosseous
- Thumb abduction (T1): Abductor pollicis brevis
Lower Limb
- Hip flexion (L1-L2): Iliopsoas
- Hip extension (L5-S1): Gluteus maximus
- Knee extension (L3-L4): Quadriceps
- Knee flexion (L5-S1): Hamstrings
- Ankle dorsiflexion (L4-L5): Tibialis anterior
- Ankle plantarflexion (S1-S2): Gastrocnemius
- Great toe extension (L5): Extensor hallucis longus
Deep Tendon Reflexes
| Reflex | Root Level | Hyperreflexia Suggests | Hyporeflexia Suggests |
|---|---|---|---|
| Biceps | C5-C6 | Upper motor neuron lesion above C5 | C5-C6 radiculopathy, peripheral neuropathy |
| Triceps | C7 | Upper motor neuron lesion above C7 | C7 radiculopathy |
| Brachioradialis | C5-C6 | Upper motor neuron lesion above C5 | C5-C6 radiculopathy |
| Knee (patellar) | L3-L4 | Upper motor neuron lesion above L3 | L3-L4 radiculopathy, femoral neuropathy |
| Ankle (Achilles) | S1 | Upper motor neuron lesion above S1 | S1 radiculopathy, peripheral neuropathy (often first lost) |
Pathological Reflexes
- Babinski sign (extensor plantar response): Upgoing great toe with fanning of other toes on stroking lateral sole; indicates upper motor neuron lesion
- Hoffman sign: Flexion of thumb and index finger when flicking middle finger; suggests cervical cord or upper motor neuron pathology
- Clonus: Sustained rhythmic contractions (more than 3 beats) with quick stretch; indicates upper motor neuron lesion
Sensory Examination
Why Test Sensation in Weakness?
The pattern of sensory involvement helps localize the lesion:
- No sensory loss: Pure motor pathology (anterior horn cell, neuromuscular junction, muscle)
- Dermatomal sensory loss: Nerve root lesion
- Peripheral nerve distribution: Mononeuropathy or mononeuritis multiplex
- Stocking-glove pattern: Length-dependent polyneuropathy
- Sensory level: Spinal cord lesion (test for level with pinprick)
- Hemisensory loss: Contralateral thalamic or cortical lesion
Coordination and Gait
Coordination Tests
Finger-nose-finger: Cerebellar dysfunction causes intention tremor and dysmetria
Heel-shin test: Cerebellar ataxia in lower limbs
Rapid alternating movements: Dysdiadochokinesia in cerebellar lesions
Note: Weakness itself can impair coordination; distinguish from true cerebellar signs
Gait Assessment
Hemiplegic gait: Circumduction of stiff leg (stroke)
Spastic gait: Stiff, scissoring legs (bilateral upper motor neuron)
Steppage gait: High stepping to clear dropped foot (peroneal neuropathy, L5 radiculopathy)
Waddling gait: Trunk sway with hip weakness (myopathy)
Trendelenburg: Pelvis drops on unsupported side (hip abductor weakness)
Functional Tests for Weakness
| Test | How to Perform | What It Assesses |
|---|---|---|
| Gower sign | Ask patient to rise from floor | Uses hands to “climb up” thighs; indicates proximal weakness (hip extensors) |
| Chair rise | Rise from seated without using arms | Proximal leg weakness (quadriceps, hip flexors) |
| Heel and toe walking | Walk on heels, then on toes | Heel walk tests dorsiflexors (L4-L5); toe walk tests plantarflexors (S1) |
| Arm elevation test | Hold arms outstretched, eyes closed | Pronator drift indicates upper motor neuron lesion; downward drift indicates weakness |
| Sustained upgaze | Look up for 60 seconds | Fatigable ptosis develops in myasthenia gravis |
| Repeated squatting | Squat and stand 10 times | Fatigable weakness in neuromuscular junction disorders |
Expected Findings by Etiology
| Condition | Tone | Reflexes | Distribution | Other Key Findings |
|---|---|---|---|---|
| Stroke (hemispheric) | Increased (after acute phase) | Hyperreflexia, Babinski | Hemiparesis, face and arm often more than leg | Hemisensory loss, aphasia, neglect possible |
| Spinal cord lesion | Increased below level | Hyperreflexia below, may be absent at level | Paraparesis or quadriparesis with sensory level | Bladder dysfunction, sensory level on trunk |
| Motor neuron disease | Mixed (spastic and flaccid) | Hyperreflexia despite atrophy | Asymmetric, multisegmental | Fasciculations, tongue atrophy, bulbar signs |
| Guillain-Barré syndrome | Decreased (flaccid) | Areflexia | Ascending, symmetric | Sensory symptoms, facial weakness, autonomic instability |
| Myasthenia gravis | Normal | Normal | Ocular, bulbar, proximal; fatigable | Ptosis, diplopia, normal sensation, improves with rest |
| Inflammatory myopathy | Normal or slightly decreased | Normal or mildly reduced late | Proximal, symmetric | No sensory loss, possible rash, dysphagia |
| Peripheral neuropathy | Decreased | Hyporeflexia (ankle lost first) | Distal, symmetric, length-dependent | Stocking-glove sensory loss, foot drop |
Important Teaching Point
The examination may be normal in early or mild disease! Many significant conditions — including early motor neuron disease, myasthenia gravis between episodes, and mild inflammatory myopathy — may have subtle or even normal examination findings. A normal neurological examination does not exclude neuromuscular disease. Serial examinations and specialized testing (electromyography, nerve conduction studies, laboratory tests) are often required to confirm the diagnosis.
5. Differential Diagnosis
Systematic approach organized by probability, duration, and anatomical localization
Acute Weakness (Hours to Days)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON | Stroke (ischemic or hemorrhagic) | Sudden onset, unilateral, vascular risk factors, associated cortical signs | Within thrombolysis window; deteriorating level of consciousness |
| COMMON | Transient ischemic attack | Sudden onset, resolves within 24 hours (usually less than 1 hour), focal deficits | High early stroke risk; requires urgent evaluation |
| COMMON | Compressive radiculopathy (disc herniation) | Radicular pain, dermatomal sensory loss, single myotome weakness | Cauda equina syndrome (bilateral, bladder involvement) |
| LESS COMMON | Guillain-Barré syndrome | Ascending symmetric weakness, areflexia, preceding infection 1-4 weeks prior | Rapid progression, respiratory compromise, autonomic instability |
| LESS COMMON | Myasthenic crisis | Known myasthenia gravis, infection or medication trigger, bulbar and respiratory weakness | Respiratory failure imminent; requires intensive care monitoring |
| LESS COMMON | Acute transverse myelitis | Bilateral weakness with sensory level, bladder dysfunction, back pain | Rapid progression; may indicate spinal cord compression |
| LESS COMMON | Spinal cord compression (malignant, abscess) | Back pain at specific level, progressive paraparesis, sphincter dysfunction | Oncologic or surgical emergency; MRI within hours |
| UNCOMMON BUT SERIOUS | Hypokalemic periodic paralysis | Episodic flaccid paralysis, triggered by carbohydrates or rest after exercise | Severe hypokalemia may cause arrhythmias |
| UNCOMMON BUT SERIOUS | Botulism | Descending paralysis, bulbar onset, pupil involvement, food exposure | Respiratory paralysis; notify public health |
| UNCOMMON BUT SERIOUS | Tick paralysis | Ascending paralysis, recent outdoor exposure, attached tick found | Rapid recovery after tick removal; search thoroughly |
Subacute Weakness (Days to Weeks)
Clinical Approach to Subacute Weakness:
- Step 1: Determine if upper or lower motor neuron pattern (or mixed)
- Step 2: Assess distribution — proximal versus distal, symmetric versus asymmetric
- Step 3: Check for sensory involvement — present suggests nerve/root/cord; absent suggests anterior horn, neuromuscular junction, or muscle
- Step 4: Look for systemic features — rash, weight loss, fever suggesting inflammatory or malignant cause
| Probability | Condition | Typical Presentation | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Inflammatory myopathy (polymyositis, dermatomyositis) | Proximal weakness over weeks, difficulty climbing stairs, rising from chair | Elevated creatine kinase, rash in dermatomyositis, no sensory loss |
| COMMON | Cervical or lumbar radiculopathy | Pain radiating in dermatomal pattern, weakness in single myotome | Positive straight leg raise or Spurling test; MRI shows disc/foraminal disease |
| LESS COMMON | Chronic inflammatory demyelinating polyneuropathy | Progressive symmetric weakness over more than 8 weeks, proximal and distal | Areflexia, elevated cerebrospinal fluid protein, demyelinating nerve conduction studies |
| LESS COMMON | Myasthenia gravis (new diagnosis) | Fatigable weakness, ptosis, diplopia, bulbar symptoms | Fluctuating symptoms, worse with activity, positive antibodies |
| LESS COMMON | Multiple sclerosis (spinal cord relapse) | Subacute myelopathy, often with sensory symptoms, prior episodes | Young adult, relapsing course, MRI shows demyelinating lesions |
| LESS COMMON | Brachial or lumbosacral plexopathy | Severe pain followed by weakness in multiple nerve distributions | May be idiopathic (neuralgic amyotrophy) or diabetic |
| UNCOMMON BUT SERIOUS | Lambert-Eaton myasthenic syndrome | Proximal weakness, autonomic symptoms (dry mouth), improves briefly with exercise | Associated with small cell lung cancer in 50-60%; check voltage-gated calcium channel antibodies |
| UNCOMMON BUT SERIOUS | Paraneoplastic syndrome | Subacute weakness with systemic symptoms, weight loss | Search for occult malignancy; check paraneoplastic antibody panel |
Chronic Weakness (Months to Years)
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Diabetic polyneuropathy | Most common cause of peripheral neuropathy in developed countries | Length-dependent, sensory predominant, distal weakness late, diabetes history |
| COMMON | Chronic radiculopathy with myelopathy (cervical spondylotic myelopathy) | Common in adults over 50 | Gait disturbance, hand clumsiness, mixed upper and lower motor neuron signs in upper limbs |
| COMMON | Inclusion body myositis | Most common acquired myopathy in patients over 50 | Asymmetric, finger flexors and quadriceps affected early, poor response to immunosuppression |
| LESS COMMON | Amyotrophic lateral sclerosis (motor neuron disease) | Incidence 2-3 per 100,000 | Progressive, mixed upper and lower motor neuron signs, no sensory loss, fasciculations |
| LESS COMMON | Charcot-Marie-Tooth disease (hereditary motor sensory neuropathy) | Most common inherited neuropathy; 1 in 2,500 | Distal weakness, pes cavus, hammer toes, family history, onset in childhood or adolescence |
| LESS COMMON | Limb-girdle muscular dystrophy | Variable; multiple genetic subtypes | Proximal weakness, elevated creatine kinase, onset typically in teens to young adulthood |
| LESS COMMON | Myotonic dystrophy | Most common adult muscular dystrophy | Distal weakness, myotonia (delayed relaxation), cataracts, cardiac conduction defects, family history |
| UNCOMMON | Spinal muscular atrophy (adult-onset) | Rare; 1 in 10,000 | Symmetric proximal weakness, lower motor neuron signs only, no sensory loss |
| UNCOMMON | Kennedy disease (spinal bulbar muscular atrophy) | Rare; X-linked | Males only, bulbar weakness, gynecomastia, sensory neuropathy, slow progression |
Anatomical Approach to Weakness
Upper Motor Neuron (Brain/Spinal Cord)
Stroke
Multiple sclerosis
Spinal cord compression
Transverse myelitis
Cervical spondylotic myelopathy
Primary lateral sclerosis
Lower Motor Neuron (Anterior Horn to Nerve)
Motor neuron disease (amyotrophic lateral sclerosis)
Spinal muscular atrophy
Poliomyelitis / Post-polio syndrome
Radiculopathy
Plexopathy
Peripheral neuropathy
Neuromuscular Junction
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Botulism
Organophosphate poisoning
Congenital myasthenic syndromes
Drug-induced (aminoglycosides, magnesium)
Muscle
Inflammatory myopathy (polymyositis, dermatomyositis)
Inclusion body myositis
Muscular dystrophies
Metabolic myopathies
Toxic/drug-induced myopathy
Endocrine myopathy
Drug-Induced Weakness
| Drug or Drug Class | Mechanism | Characteristics | Time to Resolution After Stopping |
|---|---|---|---|
| Statins (HMG-CoA reductase inhibitors) | Direct myotoxicity; rarely immune-mediated necrotizing myopathy | Proximal weakness, myalgia, elevated creatine kinase; risk increases with dose and interacting drugs | Weeks to months; immune-mediated form may persist |
| Corticosteroids | Type II fiber atrophy; altered protein metabolism | Proximal weakness, especially hip flexors; normal creatine kinase; dose and duration dependent | Weeks to months after dose reduction |
| Colchicine | Disruption of microtubules; vacuolar myopathy | Proximal myopathy with neuropathy; risk increased in renal impairment | Weeks to months |
| Hydroxychloroquine | Lysosomal dysfunction; vacuolar myopathy | Proximal weakness after prolonged use (years); may affect heart | Months; may be irreversible |
| Zidovudine (AZT) | Mitochondrial toxicity | Proximal myopathy, elevated creatine kinase, ragged red fibers on biopsy | Weeks to months |
| Immune checkpoint inhibitors | Immune-mediated myositis, myasthenia gravis | Can be severe and rapid; may coexist with myocarditis | Variable; may require immunosuppression |
| Aminoglycosides | Neuromuscular junction blockade (presynaptic) | Can precipitate or worsen myasthenic crisis | Days (after drug clearance) |
| Fluoroquinolones | Mechanism unclear; may exacerbate myasthenia gravis | Tendinopathy common; myasthenia exacerbation rare but serious | Days to weeks |
| Alcohol (chronic) | Direct myotoxicity; nutritional deficiency | Acute rhabdomyolysis or chronic proximal myopathy; often with neuropathy | Months with abstinence and nutrition |
| Amiodarone | Axonal neuropathy; occasionally myopathy | Peripheral neuropathy more common; proximal weakness less common | Months (long half-life) |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Sudden hemiparesis with facial droop | Stroke | Activate stroke protocol; CT head immediately |
| Ascending weakness with areflexia after viral illness | Guillain-Barré syndrome | Admit; monitor respiratory function; lumbar puncture |
| Fatigable ptosis and diplopia worse in evening | Myasthenia gravis | Acetylcholine receptor antibodies; ice pack test; CT chest for thymoma |
| Proximal weakness with heliotrope rash | Dermatomyositis | Creatine kinase; EMG; muscle biopsy; malignancy screening |
| Finger flexor and quadriceps weakness in elderly patient | Inclusion body myositis | Creatine kinase (may be mildly elevated); EMG; muscle biopsy |
| Mixed upper and lower motor neuron signs with fasciculations | Amyotrophic lateral sclerosis | EMG/nerve conduction studies; MRI to exclude structural causes |
| Weakness with sensory level and bladder symptoms | Spinal cord lesion (compression, myelitis) | Urgent MRI spine; if compression, neurosurgical consultation |
| Distal weakness with pes cavus and hammer toes | Charcot-Marie-Tooth disease | Nerve conduction studies; genetic testing |
| Proximal weakness with dry mouth, improves with exercise | Lambert-Eaton myasthenic syndrome | Voltage-gated calcium channel antibodies; CT chest for lung cancer |
| Weakness in patient on statin with elevated creatine kinase | Statin-induced myopathy | Stop statin; monitor creatine kinase; consider immune-mediated form if persistent |
| Radicular pain followed by weakness in arm | Cervical radiculopathy or brachial plexopathy | MRI cervical spine; EMG if plexopathy suspected |
| Descending paralysis with bulbar onset and pupil changes | Botulism | Contact public health; antitoxin; supportive care |
6. Diagnostic Investigations
A stepwise, localization-guided approach to investigating weakness
Baseline Investigations for All Patients with Unexplained Weakness
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Complete blood count | Screen for anemia, infection, malignancy | Anemia (fatigue mimic); elevated white cells (infection); macrocytosis (B12 deficiency) | Anemia causes fatigue, not true weakness; but may coexist |
| Electrolytes (sodium, potassium, calcium, magnesium, phosphate) | Identify metabolic causes of weakness | Hypokalemia (periodic paralysis, proximal weakness); hypercalcemia; hypomagnesemia | Check urgently if acute weakness; hypokalemia can be life-threatening |
| Creatine kinase (CK) | Detect muscle damage | Elevated in myopathy, rhabdomyolysis; mildly elevated in motor neuron disease | Normal CK does not exclude myopathy; very high (more than 10× normal) suggests myositis or rhabdomyolysis |
| Thyroid function tests (TSH, free T4) | Screen for thyroid-related weakness | Hypothyroidism (proximal weakness, elevated CK); hyperthyroidism (proximal weakness, normal or low CK) | Reversible cause; always check in unexplained proximal weakness |
| Renal function (creatinine, urea) | Assess for uremic neuropathy; drug clearance | Elevated creatinine may indicate rhabdomyolysis or chronic kidney disease | Important for drug dosing; colchicine toxicity increased in renal failure |
| Liver function tests | Screen for hepatic causes; baseline for medications | Elevated transaminases may be from muscle (AST, ALT can be elevated in myopathy) | If transaminases elevated, check CK to differentiate liver from muscle source |
| Glucose (fasting) or HbA1c | Screen for diabetes | Diabetic neuropathy; diabetic amyotrophy | Most common cause of peripheral neuropathy in developed countries |
| Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) | Screen for inflammatory process | Elevated in inflammatory myopathy, vasculitis, infection | Non-specific; helps support inflammatory etiology |
| Vitamin B12 | Screen for deficiency causing neuropathy or myelopathy | Low B12 causes subacute combined degeneration (myelopathy and neuropathy) | Check methylmalonic acid if B12 borderline; treat empirically if deficiency suspected |
Targeted Investigations by Suspected Etiology
If Suspecting Upper Motor Neuron Lesion (Brain or Spinal Cord)
First-Line Tests
- CT head (non-contrast): Immediate if acute stroke suspected; detects hemorrhage within minutes
- MRI brain with diffusion-weighted imaging: Gold standard for acute ischemic stroke; detects infarct within minutes of onset
- MRI spine (with contrast if indicated): Compressive lesion, myelitis, demyelination; level guided by clinical examination
Second-Line Tests
- CT angiography or MR angiography: Vascular lesion, dissection, stenosis
- Lumbar puncture: Multiple sclerosis (oligoclonal bands), transverse myelitis, infection
- Visual evoked potentials: Subclinical optic neuritis supporting multiple sclerosis diagnosis
If Suspecting Lower Motor Neuron Lesion (Anterior Horn, Root, Plexus, Nerve)
First-Line Tests
- Nerve conduction studies (NCS): Distinguishes demyelinating from axonal neuropathy; localizes entrapment
- Electromyography (EMG): Detects denervation (fibrillations, positive sharp waves); neurogenic versus myopathic pattern
- MRI spine: Radiculopathy (disc herniation, foraminal stenosis); plexopathy
Second-Line Tests
- Lumbar puncture: Guillain-Barré syndrome (albuminocytologic dissociation); chronic inflammatory demyelinating polyneuropathy
- Anti-ganglioside antibodies: GM1 (multifocal motor neuropathy); GQ1b (Miller Fisher syndrome)
- Genetic testing: Charcot-Marie-Tooth disease; hereditary neuropathies
- Nerve biopsy: Vasculitic neuropathy; amyloidosis; rarely needed
If Suspecting Neuromuscular Junction Disorder
First-Line Tests
- Acetylcholine receptor (AChR) antibodies: Positive in 85% of generalized myasthenia gravis; 50% of ocular myasthenia
- Muscle-specific kinase (MuSK) antibodies: Positive in 40% of AChR-negative myasthenia gravis
- CT chest: Thymoma present in 10-15% of myasthenia gravis; thymic hyperplasia common
Second-Line Tests
- Repetitive nerve stimulation: Decremental response (more than 10% decrement) in myasthenia gravis; incremental in Lambert-Eaton
- Single-fiber EMG: Most sensitive test for neuromuscular junction disorders; increased jitter
- Voltage-gated calcium channel antibodies: Lambert-Eaton myasthenic syndrome; associated with small cell lung cancer
- CT chest/abdomen/pelvis: Search for malignancy in Lambert-Eaton syndrome
If Suspecting Myopathy
First-Line Tests
- Creatine kinase: Usually elevated (5-50× normal in inflammatory myopathy); may be normal in steroid myopathy
- EMG: Myopathic pattern (small, polyphasic motor unit potentials; early recruitment)
- Myositis-specific antibodies: Anti-Jo-1, anti-Mi-2, anti-SRP, anti-MDA5, anti-HMGCR
Second-Line Tests
- MRI of muscles: Shows inflammation, edema, fatty replacement; guides biopsy site
- Muscle biopsy: Definitive diagnosis; distinguishes inflammatory from dystrophic and metabolic myopathies
- Genetic testing: Muscular dystrophies; metabolic myopathies (McArdle disease, mitochondrial)
- Malignancy screening: Dermatomyositis associated with malignancy; CT chest/abdomen/pelvis; age-appropriate screening
Understanding Electrodiagnostic Studies
Nerve Conduction Studies and EMG: What They Tell You
Electrodiagnostic studies are essential for localizing and characterizing neuromuscular disease. They should be performed by an experienced neurologist or neurophysiologist.
| Pattern | Nerve Conduction Studies Findings | EMG Findings | Suggests |
|---|---|---|---|
| Demyelinating neuropathy | Slowed conduction velocity; prolonged distal latency; conduction block; temporal dispersion | Neurogenic changes if axonal loss secondary | Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, Charcot-Marie-Tooth type 1 |
| Axonal neuropathy | Reduced amplitude; relatively preserved velocity | Fibrillations, positive sharp waves; neurogenic motor unit changes | Diabetic neuropathy, toxic neuropathy, Charcot-Marie-Tooth type 2 |
| Motor neuron disease | Normal sensory studies; reduced motor amplitudes | Widespread denervation in multiple myotomes; fasciculations | Amyotrophic lateral sclerosis, spinal muscular atrophy |
| Neuromuscular junction disorder | Decremental response on repetitive stimulation (myasthenia); incremental response (Lambert-Eaton) | Increased jitter on single-fiber EMG | Myasthenia gravis, Lambert-Eaton syndrome |
| Myopathy | Normal (or low motor amplitudes if severe) | Small, polyphasic motor unit potentials; early recruitment; fibrillations in inflammatory myopathy | Inflammatory myopathy, muscular dystrophy, metabolic myopathy |
Lumbar Puncture: When and Why
| Indication | Expected Findings | Clinical Context |
|---|---|---|
| Guillain-Barré syndrome | Elevated protein (more than 0.45 g/L); normal cell count (albuminocytologic dissociation) | May be normal in first week; do not delay treatment waiting for result |
| Chronic inflammatory demyelinating polyneuropathy | Elevated protein; normal or mildly elevated cells | Supports diagnosis; combined with electrodiagnostic criteria |
| Multiple sclerosis | Oligoclonal bands present in CSF but not serum; elevated IgG index | Supports diagnosis; not required if MRI criteria met |
| Infectious myelitis or encephalitis | Pleocytosis; organism-specific findings; elevated protein | Culture, viral PCR, specific antibodies based on clinical suspicion |
| Carcinomatous meningitis | Malignant cells on cytology; elevated protein; low glucose | May require repeated sampling; flow cytometry increases yield |
Muscle Biopsy: Indications and Interpretation
When to Consider Muscle Biopsy
- Suspected inflammatory myopathy with negative or non-specific antibodies
- Suspected muscular dystrophy requiring histological confirmation
- Metabolic myopathy (glycogen storage, mitochondrial) where specific diagnosis affects management
- Inclusion body myositis (characteristic inclusions on biopsy)
- When EMG shows myopathic changes but diagnosis remains unclear
Practical tip: MRI of muscles before biopsy helps identify affected but not end-stage muscles; avoid recently needled muscles (EMG artifact).
Stepwise Investigation Approach
Systematic Approach Based on Localization:
- All patients: Baseline blood tests (electrolytes, CK, thyroid function, glucose, B12)
- Upper motor neuron pattern: MRI brain and/or spine depending on level of signs
- Lower motor neuron pattern: EMG/NCS to characterize; MRI spine if radiculopathy suspected
- Neuromuscular junction: Antibodies (AChR, MuSK, VGCC); repetitive stimulation; CT chest
- Myopathy: CK, EMG, myositis antibodies; MRI muscles; biopsy if diagnosis unclear
- Mixed or unclear: Comprehensive electrodiagnostic study; consider motor neuron disease workup
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways for weakness
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Sudden hemiparesis (minutes to hours) | EMERGENT | Activate stroke protocol; CT head immediately; assess for thrombolysis/thrombectomy eligibility |
| Rapidly ascending weakness with areflexia | EMERGENT | Admit to monitored bed; serial respiratory function tests; prepare for possible intubation |
| Weakness with respiratory distress or declining forced vital capacity | EMERGENT | ICU admission; prepare for mechanical ventilation if FVC less than 20 mL/kg or NIF weaker than -30 cmH2O |
| Bilateral leg weakness with sensory level and bladder symptoms | EMERGENT | Urgent MRI spine within hours; neurosurgical consultation if compressive lesion |
| Descending paralysis with bulbar onset (diplopia, dysphagia) | EMERGENT | Consider botulism; contact public health; supportive care; antitoxin if available |
| Known myasthenia gravis with worsening weakness or new respiratory symptoms | URGENT | Assess for myasthenic crisis; check for triggers (infection, medications); monitor respiratory function closely |
| Progressive proximal weakness over days with elevated creatine kinase | URGENT | Admit for evaluation; check for rhabdomyolysis; initiate workup for inflammatory myopathy |
| New foot drop or wrist drop without trauma | URGENT | Evaluate within days; EMG/NCS to localize; MRI if radiculopathy suspected |
| Chronic progressive weakness without red flags | ROUTINE | Outpatient neurological evaluation; systematic workup over weeks |
| Fatigue without objective weakness on examination | ROUTINE | Evaluate for systemic causes (anemia, thyroid, depression); may not require neurology referral |
Step 2: Classify by Onset and Duration
Hyperacute/Acute (Minutes to Days)
Think vascular, inflammatory, or toxic
Proceed to Algorithm A
Subacute (Days to Weeks)
Think inflammatory, infectious, or compressive
Proceed to Algorithm B
Chronic (Months to Years)
Think degenerative, hereditary, or metabolic
Proceed to Algorithm C
Step 3: Follow the Appropriate Algorithm
Algorithm A: Acute Weakness (Minutes to Days)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Sudden unilateral weakness with facial droop, dysarthria | Stroke (ischemic or hemorrhagic) | CT head → if no hemorrhage and within window → consider thrombolysis/thrombectomy |
| Sudden unilateral weakness that resolved within 1 hour | Transient ischemic attack | CT/MRI brain; carotid imaging; cardiac evaluation; antiplatelet therapy; risk stratification |
| Ascending symmetric weakness with areflexia, post-infectious | Guillain-Barré syndrome | Admit; lumbar puncture; serial FVC every 4-6 hours; IVIG or plasmapheresis |
| Flaccid paralysis with severe hypokalemia | Hypokalemic periodic paralysis or secondary hypokalemia | Cardiac monitor; potassium replacement; investigate cause of hypokalemia |
| Bilateral leg weakness with back pain and sensory level | Spinal cord compression or transverse myelitis | Urgent MRI spine; if compression → neurosurgery; if myelitis → steroids after excluding infection |
| Weakness following tick exposure, ascending | Tick paralysis | Thorough search for tick (scalp, hairline); remove tick; rapid improvement expected |
Algorithm B: Subacute Weakness (Days to Weeks)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Proximal weakness with heliotrope rash or Gottron papules | Dermatomyositis | CK; myositis antibodies; EMG; MRI muscles; biopsy; malignancy screening (CT chest/abdomen/pelvis) |
| Proximal weakness, elevated CK, no rash | Polymyositis or other inflammatory myopathy | Myositis antibodies; EMG; MRI muscles; muscle biopsy; exclude inclusion body myositis if older patient |
| Fatigable weakness, ptosis worse in evening, diplopia | Myasthenia gravis | AChR and MuSK antibodies; repetitive nerve stimulation; CT chest for thymoma |
| Symmetric proximal and distal weakness over more than 8 weeks, areflexia | Chronic inflammatory demyelinating polyneuropathy | EMG/NCS (demyelinating pattern); lumbar puncture (elevated protein); consider IVIG trial |
| Severe shoulder/arm pain followed by weakness | Brachial plexopathy (neuralgic amyotrophy) | EMG/NCS (plexus localization); MRI brachial plexus; supportive care; most recover spontaneously |
| Proximal leg weakness in diabetic patient with severe thigh pain | Diabetic amyotrophy (lumbosacral radiculoplexopathy) | Optimize glucose control; pain management; physical therapy; gradual recovery over months |
Algorithm C: Chronic Weakness (Months to Years)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Progressive asymmetric weakness with mixed UMN and LMN signs, fasciculations | Amyotrophic lateral sclerosis | EMG (widespread denervation); MRI brain and spine (exclude mimics); refer to specialized ALS clinic |
| Distal weakness with pes cavus, hammer toes, onset in youth, family history | Charcot-Marie-Tooth disease | EMG/NCS; genetic testing; supportive care; orthotics; genetic counseling |
| Finger flexor and quadriceps weakness in patient over 50, poor response to steroids | Inclusion body myositis | CK (mildly elevated); EMG; muscle biopsy (rimmed vacuoles, inclusions); no effective disease-modifying therapy |
| Proximal weakness in young adult with very high CK, family history | Limb-girdle muscular dystrophy | EMG; muscle biopsy; genetic testing; cardiac evaluation; supportive care |
| Distal weakness with myotonia, cataracts, family history | Myotonic dystrophy | EMG (myotonic discharges); genetic testing (CTG repeat expansion); cardiac monitoring; multisystem management |
| Length-dependent sensorimotor neuropathy in diabetic patient | Diabetic polyneuropathy | Optimize glycemic control; EMG/NCS to confirm; treat neuropathic pain; foot care education |
| Gait difficulty with hand clumsiness, hyperreflexia in legs, age over 50 | Cervical spondylotic myelopathy | MRI cervical spine; surgical decompression if progressive or severe |
Step 4: Confirm Localization and Refine Diagnosis
| Examination Findings | Localization | Key Investigations | Top Differential |
|---|---|---|---|
| Hemiparesis, hyperreflexia, Babinski, hemisensory loss | Contralateral cerebral hemisphere | CT/MRI brain | Stroke, tumor, demyelination |
| Quadriparesis with sensory level, hyperreflexia below level | Cervical spinal cord | MRI cervical spine | Compression, myelitis, demyelination |
| Paraparesis with sensory level, upper motor neuron signs in legs | Thoracic spinal cord | MRI thoracic spine | Compression, transverse myelitis |
| Asymmetric weakness with atrophy, fasciculations, hyperreflexia | Upper and lower motor neurons (diffuse) | EMG; MRI brain and spine | Motor neuron disease (ALS) |
| Radicular pattern weakness with dermatomal sensory loss | Nerve root | MRI spine; EMG | Disc herniation, foraminal stenosis |
| Distal symmetric weakness with stocking-glove sensory loss, areflexia | Peripheral nerves (polyneuropathy) | EMG/NCS; metabolic workup | Diabetic, toxic, inflammatory neuropathy |
| Fatigable weakness, ptosis, diplopia, normal reflexes | Neuromuscular junction | AChR/MuSK antibodies; repetitive stimulation | Myasthenia gravis |
| Proximal symmetric weakness, no sensory loss, normal or reduced reflexes | Muscle | CK; EMG; muscle biopsy | Inflammatory myopathy, muscular dystrophy |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient with Guillain-Barré syndrome has FVC less than 1.5 L | Prepare for intubation; transfer to ICU | Continue IVIG or plasmapheresis; monitor for dysautonomia |
| Myasthenia patient cannot swallow safely | NPO status; nasogastric tube; assess for crisis | IVIG or plasmapheresis; avoid aminoglycosides and other contraindicated medications |
| CK is more than 10,000 U/L with weakness | IV fluids; monitor renal function; check for myoglobinuria | Investigate cause (inflammatory myopathy, rhabdomyolysis, statin toxicity) |
| Patient on statin develops weakness | Check CK; stop statin if significantly elevated | Monitor for improvement; check HMGCR antibodies if weakness persists (immune-mediated necrotizing myopathy) |
| Suspected spinal cord compression with bladder symptoms | Urgent MRI spine (within hours); dexamethasone if malignancy suspected | Neurosurgical or oncological consultation based on findings |
| AChR and MuSK antibodies are negative but myasthenia suspected | Proceed with repetitive nerve stimulation and single-fiber EMG | Consider seronegative myasthenia; trial of pyridostigmine; LRP4 antibodies if available |
| EMG shows widespread denervation in patient with weakness | MRI brain and full spine to exclude structural cause | If imaging negative and clinical picture fits, diagnose motor neuron disease; refer to specialist clinic |
| Young patient with proximal weakness and family history of muscular dystrophy | Check CK; arrange genetic testing | Cardiac evaluation (many dystrophies affect heart); genetic counseling; multidisciplinary care |
Troubleshooting: Weakness Not Responding to Treatment
Ask These Questions
- Is the diagnosis correct? — Revisit localization; consider repeating EMG; review biopsy
- Is there a second diagnosis? — Patients can have overlapping conditions (for example: myasthenia plus thyroid disease)
- Was treatment adequate? — Duration and dose of immunotherapy; compliance
- Is this a treatment-resistant condition? — Inclusion body myositis does not respond to immunosuppression
- Are there complicating factors? — Infection, medication side effects, deconditioning
- Is the weakness functional? — Consider if inconsistencies on examination; psychiatric evaluation if appropriate
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Localization before diagnosis: The most important step in evaluating weakness is determining WHERE the lesion is (upper motor neuron, lower motor neuron, neuromuscular junction, or muscle) before considering WHAT the lesion is.
Mixed upper and lower motor neuron signs = motor neuron disease until proven otherwise: Finding both hyperreflexia AND atrophy/fasciculations in the same limb is the hallmark of amyotrophic lateral sclerosis.
Respiratory monitoring saves lives in Guillain-Barré syndrome: Serial forced vital capacity measurements are more important than any other test. Intubate when FVC falls below 20 mL/kg, not when the patient becomes hypoxic.
Neck flexion strength correlates with respiratory function: A patient who cannot lift their head off the pillow likely has significant diaphragmatic weakness. Use this as a rapid bedside screen.
Think Lambert-Eaton in proximal weakness with autonomic symptoms: Dry mouth, constipation, and erectile dysfunction combined with proximal weakness that briefly improves with exercise should prompt evaluation for Lambert-Eaton syndrome and underlying malignancy.
Check the medication list: Statins, corticosteroids, colchicine, and immune checkpoint inhibitors are common causes of weakness. A thorough medication history may reveal the diagnosis immediately.
Inclusion body myositis has a distinctive pattern: Weakness of finger flexors and quadriceps in a patient over 50 that does not respond to immunosuppression is classic for inclusion body myositis. Early recognition prevents futile treatment.
Sensory involvement helps localize: Weakness WITH sensory loss suggests peripheral nerve, plexus, root, or spinal cord involvement. Weakness WITHOUT sensory loss suggests anterior horn cell, neuromuscular junction, or muscle.
Critical Pitfalls to Avoid
Confusing fatigue with weakness: Many patients say “weak” when they mean “tired.” Always verify objective weakness on examination. Fatigue without objective weakness has a different differential (anemia, depression, hypothyroidism, chronic fatigue syndrome).
Assuming normal oxygen saturation means adequate ventilation: In neuromuscular respiratory failure, hypercapnia (elevated CO2) occurs before hypoxia. A normal oxygen saturation does not exclude impending respiratory failure. Check arterial blood gas and FVC.
Missing spinal cord compression because of incomplete examination: Always check for a sensory level in patients with bilateral leg weakness. A sensory level indicates spinal cord pathology and requires urgent MRI. Missing cord compression can result in permanent paralysis.
Delaying treatment of Guillain-Barré syndrome for lumbar puncture results: The lumbar puncture may be normal in the first week. If the clinical picture is consistent, start IVIG or plasmapheresis without waiting for cerebrospinal fluid results.
Giving contraindicated medications in myasthenia gravis: Aminoglycosides, fluoroquinolones, magnesium, beta-blockers, and many other drugs can precipitate myasthenic crisis. Always check medication safety before prescribing to patients with myasthenia gravis.
Forgetting to screen for malignancy in dermatomyositis and Lambert-Eaton syndrome: Up to 30% of dermatomyositis cases and 50-60% of Lambert-Eaton cases are paraneoplastic. Age-appropriate cancer screening plus CT of chest, abdomen, and pelvis is essential.
Attributing all weakness to “old age” or deconditioning: Progressive weakness always has a cause. Elderly patients can develop motor neuron disease, myasthenia gravis, or inflammatory myopathy. Do not dismiss weakness as inevitable aging.
Stopping statins too briefly before concluding they are not the cause: Statin-induced myopathy may take weeks to months to resolve after stopping. Additionally, immune-mediated necrotizing myopathy triggered by statins persists even after drug discontinuation and requires immunosuppression.
Key Takeaways
- Distinguish true weakness from fatigue: True weakness is objective reduction in strength; fatigue is subjective sense of tiredness without objective weakness. This distinction fundamentally changes the differential.
- Localization is paramount: Determine if the lesion is upper motor neuron, lower motor neuron, neuromuscular junction, or muscle BEFORE ordering investigations. The localization drives the entire workup.
- Time course guides urgency: Hyperacute onset suggests stroke; acute ascending weakness suggests Guillain-Barré; subacute proximal weakness suggests inflammatory myopathy; chronic progressive weakness suggests degenerative or hereditary disease.
- Upper motor neuron lesions produce spasticity and hyperreflexia: But these may be absent acutely (spinal shock). Babinski sign and pyramidal distribution of weakness help identify upper motor neuron pathology.
- Lower motor neuron lesions produce flaccidity, atrophy, and fasciculations: Hyporeflexia or areflexia is typical. The pattern (dermatomal, peripheral nerve, diffuse) helps localize within the lower motor neuron pathway.
- Neuromuscular junction disorders cause fatigable weakness: Symptoms fluctuate through the day, worsen with activity, and improve with rest. Ocular and bulbar involvement is common in myasthenia gravis.
- Myopathies cause proximal weakness without sensory loss: Creatine kinase is usually elevated. The pattern of weakness, associated features (rash, myotonia), and family history guide specific diagnosis.
- Red flags require immediate action: Respiratory compromise, acute cord compression, and stroke are emergencies. Respiratory monitoring is critical in Guillain-Barré syndrome and myasthenic crisis.
- Always consider drug-induced causes: Statins, corticosteroids, and many other medications cause weakness. Review the medication list early in the evaluation.
- Do not forget paraneoplastic causes: Dermatomyositis, Lambert-Eaton syndrome, and some neuropathies may be the first manifestation of occult malignancy. Appropriate cancer screening is essential.
Quick Reference Algorithm
Systematic Approach to Weakness:
- Confirm true weakness: Distinguish from fatigue, pain-limited movement, or other mimics by objective strength testing.
- Identify red flags: Respiratory involvement, acute onset, spinal cord features, and bulbar symptoms require immediate action.
- Localize anatomically: Upper motor neuron, lower motor neuron, neuromuscular junction, or muscle based on examination findings.
- Characterize the pattern: Proximal versus distal, symmetric versus asymmetric, acute versus chronic.
- Order appropriate investigations: Baseline bloods for all; imaging, electrodiagnostics, and specialized tests guided by localization.
- Consider common and serious diagnoses: Use probability-based thinking but do not miss rare treatable conditions.
- Review medications and exposures: Drug-induced weakness is common and reversible.
- Initiate treatment and monitor response: Many causes of weakness are treatable; response to therapy may confirm the diagnosis.